IKT RSI Chart
Last 7 days
-18.7%
Last 30 days
-35.3%
Last 90 days
-45.5%
Trailing 12 Months
-59.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 141.9K | 251.8K | 324.1K | 260.5K |
2022 | 2.4M | 1.6M | 867.7K | 123.4K |
2021 | 1.8M | 3.0M | 3.3M | 3.1M |
2020 | 1.0M | 910.6K | 804.5K | 698.5K |
2019 | 0 | 0 | 0 | 1.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 16, 2022 | werner milton h. | bought | 4,000 | 0.8 | 5,000 | president and ceo |
May 27, 2022 | werner milton h. | bought | 4,880 | 0.976 | 5,000 | president and ceo |
May 20, 2022 | werner milton h. | bought | 6,000 | 0.6 | 10,000 | president and ceo |
May 19, 2022 | frattaroli joseph | bought | 2,542 | 0.644 | 3,948 | chief financial officer |
Jan 03, 2022 | werner milton h. | acquired | 44,143 | 2.02 | 21,853 | president and ceo |
Nov 17, 2021 | werner milton h. | bought | 46,558 | 1.97372 | 23,589 | president and ceo |
Aug 17, 2021 | werner milton h. | acquired | 44,143 | 2.02 | 21,853 | president and ceo |
May 14, 2021 | werner milton h. | acquired | 16,608 | 0.38 | 43,707 | president and ceo |
May 14, 2021 | werner milton h. | sold (taxes) | -77,653 | 4.59 | -16,918 | president and ceo |
Dec 28, 2020 | frattaroli joseph | acquired | 441,430 | 10.00 | 44,143 | chief financial officer |
Which funds bought or sold IKT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -6.18 | -17,354 | 104,197 | -% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | -1,411 | 12,807 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 79.00 | 79.00 | -% |
Feb 14, 2024 | Royal Bank of Canada | new | - | 3,000 | 3,000 | -% |
Feb 13, 2024 | Tower Research Capital LLC (TRC) | added | 169 | 4,459 | 7,517 | -% |
Feb 13, 2024 | MORGAN STANLEY | unchanged | - | -200 | 2,117 | -% |
Feb 13, 2024 | EDGEWOOD MANAGEMENT LLC | sold off | -100 | -23,166 | - | -% |
Feb 13, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -258,604 | - | -% |
Feb 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -4,023 | 36,465 | -% |
Unveiling Inhibikase Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Inhibikase Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 47.9B | 6.8B | -8.03 | 7 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.02 | 9.62 | ||||
BMRN | 15.7B | 2.5B | 76.24 | 6.34 | ||||
INCY | 12.1B | 3.8B | 16.19 | 3.2 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.82 | 14.42 | ||||
BBIO | 5.2B | 107.9M | -9.53 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.81 | 13.09 | ||||
ARWR | 3.0B | 240.7M | -10.2 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.79 | 3.86 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.31 | 4.36 | ||||
NVAX | 687.2M | 983.7M | -1.26 | 0.7 | ||||
CRBP | 408.0M | 881.7K | -9.15 | 466.16 | ||||
INO | 282.8M | 4.9M | -2.09 | 58.11 | ||||
IBIO | 6.9M | 2.1M | -0.25 | 2.14 |
Inhibikase Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Revenue | -100.0% | 1* | 80.00 | 116 | 65.00 | 64.00 | 7.00 | 7.00 | 4.00 | 2.00 | 328 | 1,363 | 1,407 | 170 | 38.00 | 220 | 271 | - |
Costs and Expenses | -9.2% | 4,404 | 4,848 | 6,319 | 4,779 | 4,399 | 4,520 | 4,646 | 4,687 | 5,043 | 4,799 | 3,991 | 4,032 | 1,371 | 701 | 634 | 811 | - |
S&GA Expenses | -13.7% | 1,401 | 1,623 | 1,783 | 1,925 | 1,344 | 1,539 | 1,664 | 1,670 | 1,653 | 1,645 | 1,609 | 1,601 | 1,144 | 581 | 370 | 528 | - |
R&D Expenses | -6.9% | 3,003 | 3,226 | 4,536 | 2,854 | 3,054 | 2,982 | 2,982 | 3,017 | 3,390 | 3,155 | 2,382 | 2,432 | 227 | 121 | 263 | 283 | - |
Interest Expenses | 29.9% | 226 | 174 | 424 | 237 | 56.00 | 19.00 | - | -5* | -39.69 | 157* | 8.00 | 12.00 | 7.00 | 7.00 | 8.00 | 7.00 | - |
Net Income | 9.1% | -4,177 | -4,595 | -5,777 | -4,477 | -4,279 | -4,494 | -4,639 | -4,640 | -5,041 | -4,471 | -2,636 | -2,637 | -1,207 | -670 | -421 | -547 | - |
Net Income Margin | -23.7% | -73.05* | -59.03* | -75.58* | -126.06* | -146.26* | -21.68* | -11.66* | -7.13* | -4.77* | -3.35* | -2.40* | -2.69* | -4.08* | - | - | - | - |
Free Cashflow | 16.1% | -3,442 | -4,105 | -4,565 | -5,972 | -3,556 | -5,704 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -18.9% | 14,507 | 17,881 | 22,347 | 28,163 | 24,936 | 28,581 | 33,992 | 38,390 | 42,470 | 45,869 | 49,216 | 11,874 | 14,783 | - |
Current Assets | -19.0% | 14,211 | 17,551 | 21,984 | 27,629 | 24,371 | 27,986 | 33,949 | - | 42,470 | - | - | 11,871 | 14,783 | 35.00 |
Cash Equivalents | -38.3% | 9,165 | 14,861 | 1,905 | 3,957 | 7,189 | 5,782 | 32,212 | 36,611 | 40,750 | 44,846 | 46,837 | 9,610 | 13,954 | 18.00 |
Net PPE | -8.2% | 73.00 | 80.00 | 87.00 | 231 | 237 | 242 | 43.00 | - | - | - | - | - | - | - |
Liabilities | 23.3% | 3,529 | 2,863 | 2,883 | 2,842 | 3,901 | 3,445 | 4,490 | 4,380 | 4,054 | 2,708 | 2,162 | 3,837 | 4,998 | 4,528 |
Current Liabilities | 25.4% | 3,439 | 2,742 | 2,733 | 2,664 | 3,695 | 3,213 | - | - | 4,054 | 2,708 | 1,913 | 3,589 | 4,722 | 4,253 |
Shareholder's Equity | -26.9% | 10,978 | 15,018 | 19,464 | 25,285 | 21,035 | 25,136 | 29,502 | 34,009 | 38,416 | 43,161 | 47,054 | 8,037 | 9,784 | - |
Retained Earnings | -6.7% | -66,900 | -62,722 | -58,127 | -52,349 | -47,871 | -43,592 | -39,098 | -34,458 | -29,817 | -24,776 | -20,304 | -17,668 | -15,031 | -12,183 |
Additional Paid-In Capital | 0.2% | 77,872 | 77,735 | 77,588 | 77,474 | 68,798 | 68,677 | 68,575 | 68,442 | 68,208 | 67,912 | 67,334 | 25,695 | 24,806 | 7,686 |
Shares Outstanding | 15.4% | 6,186 | 5,360 | 5,291 | 5,176 | 4,224 | 4,223 | 4,224 | 4,201 | 4,193 | 2,645 | 1,859 | 1,676 | - | - |
Float | - | - | - | 19,100 | - | - | - | 18,700 | - | - | - | 51,400 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | 16.1% | -3,442 | -4,105 | -4,565 | -5,972 | -3,556 | -5,504 | -4,355 | -3,934 | -4,095 | -2,020 | -4,246 | -3,934 | -946 | 76.00 | -2.91 | -255 | - |
Share Based Compensation | -5.8% | 122 | 130 | 125 | 123 | 100 | 102 | 133 | 123 | 266 | 352 | 322 | 591 | 154 | 140 | 140 | 140 | - |
Cashflow From Investing | -112.4% | -2,115 | 17,061 | 2,550 | -5,838 | 4,963 | -20,925 | -43.09 | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | -197391.4% | -138 | 70* | -35.99 | 8,579 | - | - | - | -204 | - | 30.00 | 41,473 | -409 | 14,884 | -67.13 | -2.45 | 250 | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue: | ||
Total revenue | $ 260,501 | $ 123,440 |
Revenue From Contract With Customer Product And Service Extensible List | us-gaap:GrantMember | us-gaap:GrantMember |
Costs and expenses: | ||
Research and development | $ 13,618,348 | $ 12,034,985 |
Selling, general and administrative | 6,731,945 | 6,217,063 |
Total costs and expenses | 20,350,293 | 18,252,048 |
Loss from operations | (20,089,792) | (18,128,608) |
Interest income | 1,060,909 | 74,453 |
Net loss | (19,028,883) | (18,054,155) |
Other comprehensive (loss) income, net of tax: | ||
Unrealized gains (losses) on marketable securities | (103,841) | 104,718 |
Comprehensive loss | $ (19,132,724) | $ (17,949,437) |
Net loss per share - basic | $ (3.57) | $ (4.28) |
Net loss per share - diluted | $ (3.57) | $ (4.28) |
Weighted average number of common share - basic | 5,333,096 | 4,223,099 |
Weighted average number of common share - diluted | 5,333,096 | 4,223,099 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,165,179 | $ 7,188,553 |
Marketable securities | 4,086,873 | 15,861,620 |
Accounts receivable | 0 | 39,881 |
Prepaid research and development | 219,817 | 1,117,616 |
Prepaid expenses and other current assets | 739,179 | 163,452 |
Total current assets | 14,211,048 | 24,371,122 |
Equipment and improvements, net | 73,372 | 236,532 |
Right-of-use asset | 222,227 | 328,643 |
Total assets | 14,506,647 | 24,936,297 |
Current liabilities: | ||
Accounts payable | 646,767 | 1,151,173 |
Lease obligation, current | 150,095 | 145,836 |
Accrued expenses and other current liabilities | 2,259,955 | 2,398,436 |
Insurance premium financing payable | 381,784 | 0 |
Total current liabilities | 3,438,601 | 3,695,445 |
Lease obligations, net of current portion | 90,124 | 205,451 |
Total liabilities | 3,528,725 | 3,900,896 |
Commitments and contingencies (see Note 14) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; 0 shares issued and outstanding at December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 shares authorized; 6,186,280 and 4,224,294 shares issued and outstanding at December 31, 2023 and 2022 | 6,186 | 4,224 |
Additional paid-in capital | 77,871,584 | 68,798,301 |
Accumulated other comprehensive income | 877 | 104,718 |
Accumulated deficit | (66,900,725) | (47,871,842) |
Total stockholders' equity | 10,977,922 | 21,035,401 |
Total liabilities and stockholders' equity | $ 14,506,647 | $ 24,936,297 |